Faculty of Pharmaceutical Sciences, University of British Columbia, 2405 Wesbrook Mall, Vancouver, BC, V6T 1Z3, Canada.
Vancouver General Hospital, 899 W 12th Ave, Vancouver, BC, V5Z 1M9, Canada.
Clin Pharmacokinet. 2017 Dec;56(12):1479-1490. doi: 10.1007/s40262-017-0548-y.
Infectious disease and pharmacokinetic textbooks indicate that vancomycin has poor penetration into the central nervous system due to its hydrophilic nature and high molecular weight. Recent literature suggests that penetration of vancomycin into cerebrospinal fluid (CSF) is higher than previously reported; therefore, we conducted a systematic review to assess the penetration of vancomycin into CSF.
We searched the MEDLINE, EMBASE, and CENTRAL electronic databases for English-language human studies evaluating serum and CSF concentrations of intravenous vancomycin.
In 13 identified studies, the CSF-to-serum ratio of vancomycin varied from 0.00 to 0.81. CSF penetration ranged 0.06-0.81 in patients with meningitis, 0.05-0.17 in ventriculitis, 0.00-0.36 in other infections, and 0-0.13 in patients without infection. Despite variable CSF penetration, 83% of patients with meningitis and 100% of patients with ventriculitis achieved clinical cure. No factor predicted vancomycin CSF penetration.
Contrary to prior belief, studies included in our review did not show universally low penetration of vancomycin into CSF. CSF vancomycin levels were variable and did not predict clinical cure.
传染病学和药代动力学教材表明,由于万古霉素具有亲水性和高分子量的特点,其很难穿透中枢神经系统。最近的文献表明,万古霉素穿透脑脊液(CSF)的能力比之前报道的要高;因此,我们进行了一项系统评价,以评估万古霉素穿透脑脊液的情况。
我们在 MEDLINE、EMBASE 和 CENTRAL 电子数据库中搜索了评估静脉万古霉素血清和脑脊液浓度的英语人类研究。
在 13 项确定的研究中,万古霉素的脑脊液与血清比值从 0.00 到 0.81 不等。脑膜炎患者的万古霉素穿透率为 0.06-0.81,脑室炎患者为 0.05-0.17,其他感染患者为 0.00-0.36,无感染患者为 0-0.13。尽管脑脊液穿透率存在差异,但 83%的脑膜炎患者和 100%的脑室炎患者临床治愈。没有因素可以预测万古霉素的脑脊液穿透率。
与之前的观点相反,我们的综述纳入的研究并未普遍显示万古霉素对脑脊液的低穿透率。脑脊液万古霉素水平存在差异,且无法预测临床治愈。